Stay updated with breaking news from About Multiple Sclerosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients
(0) The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1 The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod's efficacy and safety 1,2,3 Approval builds on Janssen's deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS Janssen, the Pharmaceutical Companies of Johnson J...